Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.
about
The role and clinical implications of G6PI in experimental models of rheumatoid arthritisDifferential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-kappaB binding activity and TNF-alpha secretion of T cellsCD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in miceTreatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two childrenImmunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic miceTreatment of vasculitis.Peripheral CD4CD8 double positive T cells with a distinct helper cytokine profile are increased in rheumatoid arthritis.Involvement of CD4+ T lymphocytes in induction of severe destructive Lyme arthritis in inbred LSH hamstersIntra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology.Principles of antibody therapy.Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid jointsCDR3 sequence motifs shared by oligoclonal rheumatoid arthritis synovial T cells. Evidence for an antigen-driven response.Immunotherapy of rheumatoid arthritis.Cell therapy for autoimmune diseases: does it have a future?Perturbation of the T cell repertoire in rheumatoid arthritis.Autoregulation of Th1-mediated inflammation by twist1.Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugatesProtective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection.Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery.Genome-wide DNA methylation patterns in CD4+ T cells from Chinese Han patients with rheumatoid arthritis.Murine ultrasound-guided transabdominal para-aortic injections of self-assembling type I collagen oligomers.Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.Drug treatment of arthritis. Update on conventional and less conventional methods.Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis?Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice.Monoclonal antibodies in the treatment of rheumatoid arthritis.Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction?A review on the strategies for the development and application of new anti-arthritic agents.The role of T-lymphocytes and cytokines in rheumatoid arthritis.Photodynamic treatment of rheumatoid and inflammatory arthritis.Characterization of the natural immune response of rhesus monkey CD4+ve T cells to the bacterial antigen streptolysin O (SLO).Clinical immunology.Effects of anti-CD4 antibodies on the release of IL-6 and TNF-alpha in whole blood samples from patients with systemic lupus erythematosus.Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients.Depletion of alpha/beta T cells by a monoclonal antibody against the alpha/beta T cell receptor suppresses established adjuvant arthritis, but not established collagen-induced arthritis in rats.Involvement of autoimmunity against type II collagen in the development of arthritis in mice transgenic for the human T cell leukemia virus type I tax gene.Obstacles to Anti-CD4 Therapy in Rheumatoid Arthritis.Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.
P2860
Q24799403-D5A8C00A-1A44-4EE5-82B0-C1CC22159308Q24807250-3ABEF82F-3447-48EA-A411-EA67F1C48280Q30388433-D6CD7897-B678-4FA7-A67E-FC24F4478CF2Q30982756-34E2A650-7C9D-42D2-9D9E-01519236FDF4Q33578439-91103BFD-7894-4529-BC9E-A50EEC75585AQ34006052-A512A2C1-E857-45D7-AED4-BC2F8D2B7709Q34403507-3CAAE537-E291-4007-B03D-2F4D4EB5075CQ35131197-8271E58C-D140-4C8D-8D32-C052EE393557Q35456712-2FF2F2A3-B914-40B1-AE04-539208AB5DFCQ35548626-C33654E8-A276-4B02-9CA0-F2D5E6776FBFQ35660057-CAA750BE-5627-47EC-AFF1-58A6220F7157Q35764161-4F74D6A4-7A0D-4D84-946E-69D572B3706CQ35824763-374CAE5D-23C5-41B7-922B-4C7BE8A16FB3Q35881647-96DB353D-1CAA-478A-A85D-18181A3095C4Q35916008-F89CEC21-1A00-43B8-9457-709CA661F4C1Q36735976-030536AD-D118-4103-A3A0-A998A62A8EABQ36851881-BE7E364B-AEC9-4195-92F8-435C68F01617Q37238542-AF1C6190-7CB9-411F-8F67-58089A1B7533Q37460580-14C52633-4841-47FB-8E93-37691EC82229Q38067265-4D0CC9BF-442F-4986-B38A-30B48D270E76Q38443150-9DEE4850-7A13-46AF-A193-3B41DD5CD6CAQ38765380-0E1B65E2-1C8B-4881-8676-8C40DC290AD7Q38822723-39A503E0-8415-42F0-828E-2523D257475BQ39452477-46AA8691-61C0-4312-9996-8FA802B42003Q39493657-FC493DD3-7FCD-435D-B7C4-88A6BE772243Q39706642-D54DBCDF-026F-41FB-947C-A57D1B56BAA2Q40396183-AB873340-E0D4-4A7E-8F48-CD0C9B29D803Q40693747-3D3CA77E-009B-436A-8385-F37C7C6A03D5Q40901167-33C62FF0-7B86-4213-8517-7681B9355C67Q40932806-3ADD0D2E-4FF1-483B-9744-231E9A9889E6Q41085279-28494176-38AC-436C-9BB0-C7E5B4728C7DQ41226325-D05BB81C-A055-4626-A720-DD40E0E97863Q41262144-EBA82203-6342-4DC5-AEBA-04A7CDD6CFC4Q41843290-9829F159-0862-49D2-833F-AB3AE21BAF71Q42481349-FC3EEA3C-D151-4438-BEEE-0A4C1228B4B1Q42635758-4B0D0252-6D3C-4A15-AD3B-E9325538B8FBQ42768802-FFE397F7-D231-4646-A507-EA8305D15269Q45751487-705416C7-C9BC-4B6D-9BA0-84D4FFD55514Q46192663-D3E5DD5A-6CAA-49BF-A1C0-195871509907Q47380976-B7EEC52D-40DB-4602-A226-4CCABFB15C19
P2860
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.
@en
type
label
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.
@en
prefLabel
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.
@en
P2093
P356
P1476
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.
@en
P2093
P304
P356
10.1002/ART.1780340202
P577
1991-02-01T00:00:00Z